Literature DB >> 23602400

Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.

Taiji Goto1, Akiko Shiina, Toshiharu Yoshino, Kiyoshi Mizukami, Kazuki Hirahara, Osamu Suzuki, Yoshitaka Sogawa, Tomoko Takahashi, Tsuyoshi Mikkaichi, Naoki Nakao, Mizuki Takahashi, Masashi Hasegawa, Shigeki Sasaki.   

Abstract

2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC50=150 nM). A number of derivatives with a variety of 4-amino substituents and fused bicyclic pyrimidines were synthesized. Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC50=25 nM). Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC50=7.5 nM) and TNF-α production in mouse splenocytes (IC50=9.8 nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID50=18 mg/kg). The binding mode of the new inhibitor (31e) in the catalytic site of PDE4B is presented based on an X-ray crystal structure of the ligand-enzyme complex.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23602400     DOI: 10.1016/j.bmcl.2013.03.104

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.

Authors:  Mark E Gurney; Emily C D'Amato; Alex B Burgin
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 2.  Research developments in the syntheses, anti-inflammatory activities and structure-activity relationships of pyrimidines.

Authors:  Haroon Ur Rashid; Marco Antonio Utrera Martines; Adriana Pereira Duarte; Juliana Jorge; Shagufta Rasool; Riaz Muhammad; Nasir Ahmad; Muhammad Naveed Umar
Journal:  RSC Adv       Date:  2021-02-03       Impact factor: 3.361

3.  Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors.

Authors:  Naga Srinivas Tripuraneni; Mohammed Afzal Azam
Journal:  J Mol Model       Date:  2015-10-26       Impact factor: 1.810

4.  Structural basis for the design of selective phosphodiesterase 4B inhibitors.

Authors:  David Fox; Alex B Burgin; Mark E Gurney
Journal:  Cell Signal       Date:  2013-12-19       Impact factor: 4.315

5.  Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition.

Authors:  Alexander McGirr; Tatiana V Lipina; Ho-Suk Mun; John Georgiou; Ahmed H Al-Amri; Enoch Ng; Dongxu Zhai; Christina Elliott; Ryan T Cameron; Jonathan G L Mullins; Fang Liu; George S Baillie; Steven J Clapcote; John C Roder
Journal:  Neuropsychopharmacology       Date:  2015-08-14       Impact factor: 7.853

6.  Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners.

Authors:  Kirsty F Houslay; Frank Christian; Ruth MacLeod; David R Adams; Miles D Houslay; George S Baillie
Journal:  Biochem J       Date:  2016-12-19       Impact factor: 3.857

Review 7.  Phosphodiesterase 4B: Master Regulator of Brain Signaling.

Authors:  Amy J Tibbo; George S Baillie
Journal:  Cells       Date:  2020-05-19       Impact factor: 6.600

8.  Synthesis and Antioxidant Activity of 7-Thio Derivatives of 6,7-Dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione.

Authors:  Yuriy M Kononevich; Ludmila S Bobkova; Alexander S Smolski; Anatoly M Demchenko
Journal:  Sci Pharm       Date:  2014-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.